Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.81 |
| ▸ | MMP1 | P03956 | 16/20 | 0.81 |
| ▸ | PGR | P06401 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11812693 | 0.93 | NR3C1 (0.83) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL7547 | 0.93 | NR3C1 (0.83) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL6986508 | 0.93 | NR3C1 (0.83) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL1265487 | 0.92 | NR3C1 (0.82) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL147590 | 0.92 | NR3C1 (0.82) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL2323155 | 0.92 | NR3C1 (0.83) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL15538807 | 0.92 | NR3C1 (0.78) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL8534300 | 0.91 | NR3C1 (0.80) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL25372269 | 0.91 | NR3C1 (0.87) | NR3C1MMP1PGRCYP3A4MEN1 | |
| SCHEMBL122396 | 0.91 | NR3C1 (0.87) | NR3C1MMP1PGRCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2969435-B1 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | PROMEGA CORP (US) | 2021-11-03 | — | — | EP | claimed |
| US-20210340593-A1 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | PROMEGA CORPORATION | 2021-11-04 | — | — | US | disclosed |
| EP-2969435-B1 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | PROMEGA CORP (US) | 2021-11-03 | — | — | EP | disclosed |
| US-11072811-B2 | Substrates for covalent tethering of proteins to functional groups or solid surfaces | PROMEGA CORPORATION (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072812-B2 | Substrates for covalent tethering of proteins to functional groups or solid surfaces | PROMEGA CORPORATION (US) | 2021-07-27 | — | — | US | disclosed |
| US-20180117171-A1 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2018-05-03 | — | — | US | disclosed |
| WO-2016161372-A1 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-2969435-A1 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | Promega Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140322794-A1 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | PROMEGA CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322738-A1 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | PROMEGA CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2014151282-A1 | SUBSTRATES FOR COVALENT TETHERING OF PROTEINS TO FUNCTIONAL GROUPS OR SOLID SURFACES | PROMEGA CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117171-A1 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | FCGR1A, FCGR3B, FCER2 | NR3C1 233/4885MMP1 2488/4885PGR 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.